Literature DB >> 925885

Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

P V Pedersen.   

Abstract

Mesh：

Substances：

Year:  1977        PMID： 925885     DOI： 10.1007/bf01061732

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN： 0090-466X


× No keyword cloud information.
  8 in total

1.  Do you need a pharmacokinetic model, and, if so, which one?

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1975-12

2.  The formulation and testing of models.

Authors:  M BERMAN
Journal:  Ann N Y Acad Sci       Date:  1963-05-10       Impact factor: 5.691

3.  The routine fitting of kinetic data to models: a mathematical formalism for digital computers.

Authors:  M BERMAN; E SHAHN; M F WEISS
Journal:  Biophys J       Date:  1962-05       Impact factor: 4.033

4.  Testing for serial correlation in least squares regression. I.

Authors:  J DURBIN; G S WATSON
Journal:  Biometrika       Date:  1950-12       Impact factor: 2.445

5.  COMPT, a time-sharing program for nonlinear regression analysis of compartmental models of drug distribution.

Authors:  M Pfeffer
Journal:  J Pharmacokinet Biopharm       Date:  1973-04

6.  A versatile digital computer program for non-linear regression analysis.

Authors:  G L Atkins
Journal:  Biochim Biophys Acta       Date:  1971-12-21

7.  The solution of pharmacological problems with computers. 8. Non first-order models of drug metabolism.

Authors:  E Krüger-Thiemer; R R Levine
Journal:  Arzneimittelforschung       Date:  1968-12

8.  Mathematical models in medicine: a diagnosis.

Authors:  G C Nooney
Journal:  J Chronic Dis       Date:  1966-04
  8 in total
  87 in total

1.  Quantitative determination of atracurium in human plasma using high-performance liquid chromatography.

Authors:  R Okutani; K Kono; F M DeBros; D M Philbin
Journal:  J Anesth       Date:  1988-09-01       Impact factor: 2.078

2.  Simple methods for estimation of mean residence time and steady-state volume of distribution from continuous-infusion data.

Authors:  W R Gillespie
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

Review 3.  Mean time parameters in pharmacokinetics. Definition, computation and clinical implications (Part II).

Authors:  P Veng-Pedersen
Journal:  Clin Pharmacokinet       Date:  1989-12       Impact factor: 6.447

4.  Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.

Authors:  Wojciech Krzyzanski; Sukyung Woo; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-25       Impact factor: 2.745

5.  Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.

Authors:  Srividya Neelakantan; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pediatr Int       Date:  2009-02       Impact factor: 1.524

6.  A mathematical modeling approach to quantify the role of phlebotomy losses and need for transfusions in neonatal anemia.

Authors:  Matthew R Rosebraugh; John A Widness; Demet Nalbant; Peter Veng-Pedersen
Journal:  Transfusion       Date:  2012-10-04       Impact factor: 3.157

7.  Pharmacokinetics and plasma-concentration-effect relationships of prenalterol in cardiac failure.

Authors:  E J Sainsbury; D Fitzpatrick; H Ikram; M G Nicholls; E A Espiner; J J Ashley
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants.

Authors:  Matthew R Rosebraugh; John A Widness; Demet Nalbant; Gretchen Cress; Peter Veng-Pedersen
Journal:  Pediatr Res       Date:  2013-11-11       Impact factor: 3.756

9.  Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietin.

Authors:  Peter Veng-Pedersen; Kevin J Freise; Robert L Schmidt; John A Widness
Journal:  J Pharm Pharmacol       Date:  2008-10       Impact factor: 3.765

10.  Pharmacokinetic studies in man with gallamine triethiodide. I. Single and multiple clinical doses.

Authors:  M I Ramzan; E J Triggs; C A Shanks
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.